Scheduled to address investors at next week’s virtual event, Sharps Technology (NASDAQ: STSS) aims to spotlight its advancements in smart-safety syringes—a corner of the medical device sector gaining traction amid global demand for sustainable healthcare solutions.
May 21, 2025
Presentation to be webcast live at 1:00 p.m. ET
NEW YORK, May 21, 2025 — Sharps Technology, Inc. (NASDAQ: STSS), a pioneer in high-efficiency medical safety devices, announced today that CEO Robert Hayes will present at the Aegis Capital Corp. 2025 Virtual Conference on May 22. The presentation will outline the company’s progress in redefining syringe technology through its ultra-low waste systems and specialized polymer innovations, which have positioned Sharps as a disruptor in pharmaceutical packaging.
Key Presentation Highlights:
- Speaker: Robert Hayes, CEO
- Date: May 22, 2025
- Time: 1:00 p.m. ET
- Webcast: Access here
Strategic Innovations Driving Growth
Sharps Technology has carved a niche in the $10B+ prefilled syringe market with its patented safety designs, which integrate passive and active mechanisms to minimize drug waste—a critical advantage as healthcare providers prioritize cost-efficiency. The company’s proprietary copolymer syringes, manufactured at its Hungary-based facility, are engineered to maintain drug stability, addressing a persistent challenge in biologics and vaccine delivery. Analysts suggest these innovations could position Sharps to capture market share as regulators push for stricter safety standards globally.
Forward-Looking Statements
This release contains forward-looking statements regarding operational expectations, market expansion, and product pipelines. Such statements involve risks, including regulatory approvals, competition, and capital market conditions. Investors are cautioned that actual results may differ materially due to these and other factors outlined in SEC filings.
FAQ
What differentiates Sharps’ syringes from competitors?
Sharps’ syringes utilize dual safety mechanisms and polymer tech to reduce drug waste by up to 20% compared to traditional models, a key cost-saving metric for healthcare systems.
Why is the Hungary facility strategically important?
The facility provides proximity to European pharmaceutical hubs and supports scalable production to meet rising demand in transatlantic markets.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/642.html
